Sanofi (NASDAQ: SNY), a French multinational pharmaceutical company, has administered the first dose to a patient in the second part of a Phase I/II clinical trial for the trifunctional NK cell engager SAR443579, targeting blood cancers. The announcement was made by fellow French biotechnology company Innate Pharma (NASDAQ: IPHA) this week. The trial will focus on patients with relapsed or refractory acute myeloid leukemia (r/rAML), B-cell acute lymphoblastic leukemia, and high-risk myelodysplasia. The anti-CD123 NKp46xCD16 has demonstrated promising clinical efficacy in r/rAML during the Phase I dose escalation stage.
The polyspecific biologic, SAR443579, is a product of a 2016 collaboration between Sanofi and Innate Pharma, utilizing Innate’s proprietary platform. As a result of this milestone, Innate will receive a payment of EUR 4 million (USD 4.2 million) from Sanofi.
According to the press release, SAR443579 has been granted a fast-track designation by the U.S. Food and Drug Administration (FDA) for the treatment of AML in the United States. – Flcube.com
